Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock ¥58.00, price ¥135, that is 57.1% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range ¥108.00 – ¥485.80 · fair‑value band ¥29.80 – ¥79.88 · the ¥135.33 price screens above the ¥58.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Zhangzhou Pientzehuang Pharmaceutical Co in your weekly email
Every Wednesday you see whether Zhangzhou Pientzehuang Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhangzhou Pientzehuang Pharmaceutical., Ltd., together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally.
Show moreShow less
The company offers traditional Chinese medicines and health products in various forms, including capsule, ointment, tablet, syrup, and pill; health care food and functional drinks; special efficacy cosmetics; and household chemicals under the Pien Tze Huang brand name.
It is also involved in the sale of food; production of skin, hair, and oral care daily products; biotechnology and medical device research and development; sale of medical machinery; and online wholesale and retail.
The company's products are used for liver diseases, cardiovascular and cerebrovascular, cancer, cold, dermatology, and other applications. It exports its products. The company was founded in 1956 and is based in Zhangzhou, China.
Zhangzhou Pientzehuang Pharmaceutical., Ltd. operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
Stock analysis
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) currently trades at ¥135.33, while our model-based Fair Value estimate is ¥58.00, 57% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥86.93 per share, and 1 of the 17 models we run sit above the ¥135.33 price.
Bear case: the Asset-Based group reads lowest at ¥12.68, and 16 of the 17 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥29.80 (bear) to ¥79.88 (bull), the price of ¥135.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2013: revenue and profit before it include the divested business. Growth is measured afresh from 2013.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd reported revenue of 9.0B CNY in FY2025 versus 8.0B CNY in FY2021, a compound +2.9%/yr. Reported net income was 2.2B CNY in FY2025, compounding −2.9%/yr from FY2021.
Key figures
Market cap 81.6B CNY (≈ $12.3B) Large · P/E ratio 45.1 · P/S ratio 9.96 · EPS (TTM) ¥3.00 · Dividend yield 2.0% · Net margin 22.1% · Return on equity 11.7% · Return on assets (EBIT) 19.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (medium confidence).
What moves the price
The share trades about 26% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −57%, 600436 screens richer than that median.
Fair Value models
Bear¥29.80Fair Value ¥58.00Bull¥79.88
Price ¥135.33 · Downside -57.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.3058 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2013: revenue and profit before it include the divested business. Growth is measured afresh from 2013.
Revenue growth 1 year
−16.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic). Over 10 years: +16.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+7.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.2%
Dividend (yield on the price)2.0%
Per share before 2013divided by the spin-off factor 1.105
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.2% vs 16.6%, slowing
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 25%
AI conclusion: Moderate margin signals offer limited stability but are offset by weak cash conversion and heavy dependence on a single flagship product.
Main risk: Policy tightening combined with rising competition in the traditional Chinese medicine segment threatens margins and demand for the flagship product.
Zhangzhou Pientzehuang has posted repeated profit drops as policy tightening and competition intensify in its traditional Chinese medicine segment. The chairman's resignation last week adds uncertainty to a business still heavily tied to its flagship product. Can new leadership stabilize operations amid these pressures, or will the underlying challenges persist?
Compare Zhangzhou Pientzehuang Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−57.1% · Bottom 25%
Profitability
Return on equity (12 months)11.7% · Above median
Return on assets12.3% · Top 25%
Net margin (12 months)22.1% · Top 25%
Operating margin (12 months)19.4% · Above median
Growth and dividend
Revenue growth (quarter YoY)−18.1% · Bottom 25%
Dividend yield (12 months)2.0% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (12 months)45.1× · Priciest 25%
P/B5.62× · Priciest 25%
P/S (12 months)9.96× · Priciest 25%
EV/EBITDA44.2× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 19
FUTURE (revenue growth)0· sector 34
PAST (return on equity)47· sector 41
HEALTH (low debt)100· sector 93
DIVIDEND (yield)39· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhangzhou Pientzehuang Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600436
Frequently asked questions
Is Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of ¥58.00 versus a price of ¥135.33, about 57% lower (overvalued).
What is the fair value of 600436?
Our model-based fair value for Zhangzhou Pientzehuang Pharmaceutical Co Ltd is ¥58.00 (as of Nov 3, 2026), built from audited fundamentals. The current price: ¥135.33.
What is the quality score of 600436?
Zhangzhou Pientzehuang Pharmaceutical Co Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
Our model-based price target is the fair value of ¥58.00 (as of Nov 3, 2026) from 17 valuation models. Cautious scenario ¥29.80, optimistic scenario ¥79.88. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥58.00, about 57% lower versus a price of ¥135.33 (overvalued). Cautious scenario ¥29.80, optimistic scenario ¥79.88. The calculation is refreshed regularly with new filings.
What is the revenue of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
Zhangzhou Pientzehuang Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 8.2B CNY (latest available figure, as of Nov 3, 2026).
Does Zhangzhou Pientzehuang Pharmaceutical Co Ltd pay a dividend?
Zhangzhou Pientzehuang Pharmaceutical Co Ltd currently shows a dividend yield of 1.95% relative to its recent price (as of Nov 3, 2026).
What is the intrinsic value of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhangzhou Pientzehuang Pharmaceutical Co Ltd it is ¥58.00 per share (as of Nov 3, 2026), against a price of ¥135.33. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 600436 trades above its calculated fair value: price ¥135.33, fair value ¥58.00, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600436?
No. The price is what the market pays today (¥135.33); the fair value is what the company's own numbers justify (¥58.00). For Zhangzhou Pientzehuang Pharmaceutical Co Ltd the two are ¥77.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhangzhou Pientzehuang Pharmaceutical Co Ltd worth?
The market values Zhangzhou Pientzehuang Pharmaceutical Co Ltd at about 81.6B CNY (market capitalisation, as of Nov 3, 2026). Per share that is ¥135.33; our models calculate a fair value of ¥58.00 per share.
What do the bullish and bearish scenarios say about 600436?
Our models span a range for Zhangzhou Pientzehuang Pharmaceutical Co Ltd: cautious scenario ¥29.80, base ¥58.00, optimistic ¥79.88 per share (as of Nov 3, 2026, price ¥135.33). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 600436?
Zhangzhou Pientzehuang Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 45.1 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥58.00 is built from several models across several years. Other multiples: P/B 5.6, P/S 10.0, EV/EBITDA 44.2.
How solid is the balance sheet of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
Balance-sheet figures for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (as of Nov 3, 2026): return on equity 11.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 600436 from its 52-week high?
Zhangzhou Pientzehuang Pharmaceutical Co Ltd trades at ¥135.33, about 26% below its 52-week high of ¥182.23 and 25% above the low of ¥108.00 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of ¥58.00 is for.
Which stocks are comparable to Zhangzhou Pientzehuang Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price ¥135.33, calculated fair value ¥58.00 (−57%), Quality Score 53/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600436 calculated?
We run Zhangzhou Pientzehuang Pharmaceutical Co Ltd through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥58.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Zhangzhou Pientzehuang Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
The closing price on Nov 5, 2026 was ¥135.33. Our model-based fair value is ¥58.00, about 57% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhangzhou Pientzehuang Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥79.88). The favourable scenario is already priced in. The model range is unusually wide (¥29.80 to ¥79.88). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) come from?
Earnings per share at Zhangzhou Pientzehuang Pharmaceutical Co Ltd grew +22.3 % a year from 2013 to 2024. Broken into its drivers: revenue per share +22.5 %, EBIT margin +0.3 %, tax rate +0.0 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Zhangzhou Pientzehuang Pharmaceutical Co Ltd
How large is the market capitalisation of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
The market capitalisation of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 81.6B CNY (≈ $12.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
The price-to-sales ratio of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 9.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
Earnings per share at Zhangzhou Pientzehuang Pharmaceutical Co Ltd are ¥3.00 (price ÷ EPS = P/E 45.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
The dividend yield of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 2.0% (payout 88.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
The net margin of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 22.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
The return on equity (ROE) of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 11.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
On an EBIT basis the return on assets of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 19.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
The operating margin of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is 19.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
Revenue at Zhangzhou Pientzehuang Pharmaceutical Co Ltd is growing −18.1% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436)?
Earnings per share at Zhangzhou Pientzehuang Pharmaceutical Co Ltd are growing −20.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) generate?
The free cash flow of Zhangzhou Pientzehuang Pharmaceutical Co Ltd is −263M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) hold?
Zhangzhou Pientzehuang Pharmaceutical Co Ltd holds more cash than debt, 382M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Zhangzhou Pientzehuang Pharmaceutical Co Ltd in the live analysis
One click puts Zhangzhou Pientzehuang Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026